

# *References*

- Abadie P, Boulenger JP, Benali K, Barre L, Zarifian E, Baron JC (1999): Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study. *Eur J Neurosci* 11:1470-1478.
- Abelson JL, Nesse RM (1990): Cholecystokinin-4 and panic [letter; comment]. *Arch Gen Psychiatry* 47:395.
- Abelson JL, Nesse RM (1994): Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses [see comments]. *Biol Psychiatry* 36:73-83.
- Abelson JL, Nesse RM, Vinik AI (1994): Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. *Biol Psychiatry* 36:84-96.
- Adinoff R, Devous MD, Best SM, George MS, Alexander D, Payne K (2001): Limbic responsiveness to procaine in cocaine-addicted subjects. *Am J Psychiatry* 158:390-398.
- Adolphs R, Tranel D, Damasio H, Damasio A (1994): Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala [see comments]. *Nature* 372:669-672.
- Albus M, Zahn TP, Breier A (1992): Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. *Eur Arch Psychiatry Clin Neurosci* 241:337-344.
- American Psychiatric Association Committee on Nomenclature and Statistics (1980): Diagnostic and statistical manual of mental disorders (3rd. ed.) DSM-III . Washington DC: American Psychiatric Press.
- American Psychiatric Association Committee on Nomenclature and Statistics (1987): Diagnostic and Statistical Manual of Mental Disorders (3rd ed., revised) , 3 ed. Washington DC: The Association.
- American Psychiatric Association Committee on Nomenclature and Statistics (1994): Diagnostic and Statistical Manual of Mental Disorders: edition 4 (DSM-IV) . Washington DC: American Psychiatric Association.
- American Psychiatric Association Committee on Nomenclature and Statistics (1998): Practice guideline for the treatment of patients with panic disorder. *Am J Psychiatry* 155:1-34.
- Bakker A, van Balkom AJLM, van Dyck R (2000): Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. *Int Clin Psychopharm* 15 Suppl. 2:S25-S30.
- Battaglia M, Bertella S, Ogliari A, Bellodi L, Smeraldi E (2001): Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. *Arch Gen Psychiatry* 58:114-119.
- Baxter LRJ, Mazziotta JC, Phelps ME, Selin CE, Guze BH, Fairbanks L (1987a): Cerebral glucose metabolic rates in normal human females versus normal males. *Psychiatry Res* 21:237-245.
- Baxter LRJ, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH et al (1988): Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. *Am J Psychiatry* 145:1560-1563.
- Baxter LRJ, Thompson JM, Schwartz JM, Guze BH, Phelps ME, Mazziotta JC et al (1987b): Trazodone treatment response in obsessive-compulsive disorder—correlated with shifts in glucose metabolism in the caudate nuclei. *Psychopathology* 20 Suppl 1:114-122.
- Baxter LJ, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC et al (1992): Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. *Arch Gen Psychiatry* 49:681-689.
- Beard,GM (1881): Symptoms of Neurasthenia. In Beard,GM, editor. *A practical Treatise on Nervous Exhaustion (Neurasthenia), Its Symptoms, Nature, Sequence, Treatment*. New York: Putnam's Sons.
- Beinfelt MC, Palkovits M (1981): Distribution of cholecystokinin in the hypothalamus and the limbic system of the rat. *Neuropeptides* 2:123-129.
- Benedikt M (1870): Ueber "Platzschwindel". *Allgem Wiener Med Zeitung* 15:488-489.

- Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A et al (1995): Functional neuroanatomy of CCK<sub>4</sub>-induced anxiety in normal healthy volunteers [see comments]. *Am J Psychiatry* 152:1180-1184.
- Benkelfat C, Nordahl TE, Semple WE, King AC, Murphy DL, Cohen RM (1990): Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. *Arch Gen Psychiatry* 47:840-848.
- Bennett JA, Moioffer M, Stanton SP, Dwight M, Keck PE (1998): A risk-benefit assessment of pharmacological treatments for panic disorder. *Drug Safety* 18:419-430.
- Bertani A, Bellodi L, Bussi R, Caldirola D, Cucchi M, Perna G (2003): The Effect of One-Week Treatment with Venlafaxine on 35% CO<sub>2</sub> Hyperreactivity in Patients with Panic Disorder: An Open Study. *J Clin Psychopharmacol* 23:106-108.
- Bertani A, Caldirola D, Bussi R, Bellodi L, Perna G (2001): The 35% CO<sub>2</sub> hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. *J Clin Psychopharmacol* 21:262-267.
- Birbaumer N, Grodd W, Diedrich O, Klose U, Erb M, Lotze M et al (1998): fMRI reveals amygdala activation to human faces in social phobics. *Neuroreport* 9:1223-1226.
- Bisaga A, Katz JL, Antonini A, Wright CE, Margoueff C, Gorman JM et al (1998): Cerebral glucose metabolism in women with panic disorder. *Am J Psychiatry* 155:1178-1183.
- Boshuisen ML, Slaap BR, Vester-Blokland ED, Den Boer JA (2001): The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. *Int Clin Psychopharmacology* 16:363-368.
- Boshuisen ML, Ter Horst GJ, Paans AMJ, Reinders A-ATS, den Boer JA (2002): rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. *Biol Psychiatry* 52:126-135.
- Bourin M, Malinge M, Guitton B (1995): Provocative agents in panic disorder. *Therapie* 50:301-306.
- Bradwejn J (1993): Neurobiological investigations into the role of cholecystokinin in panic disorder. *J Psychiatry Neurosci* 18:178-188.
- Bradwejn J, de Montigny C (1984): Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. *Nature* 312:363-364.
- Bradwejn J, Koszycki D (1991): Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 15:237-239.
- Bradwejn J, Koszycki D (1994a): Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. *Am J Psychiatry* 151:261-263.
- Bradwejn J, Koszycki D (1994b): The cholecystokinin hypothesis of anxiety and panic disorder. *Ann N Y Acad Sci* 713:273-282.
- Bradwejn J, Koszycki D (2001): Cholecystokinin and panic disorder: past and future clinical research strategies. *Scand J Clin Lab Invest Suppl* :19-27.
- Bradwejn J, Koszycki D, Annable L, Couetoux-du TA, Reines S, Karkanias C (1992a): A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. *Biol Psychiatry* 32:903-912.
- Bradwejn J, Koszycki D, Bourin M (1991a): Dose ranging study of the effects of cholecystokinin in healthy volunteers. *J Psychiatry Neurosci* 16:91-95.
- Bradwejn J, Koszycki D, Couetoux-du TA, Paradis M, Bourin M (1994a): Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. *Psychopharmacology* 114:257-261.
- Bradwejn J, Koszycki D, Couetoux-du TA, van Megen H, den Boer J, Westenberg H (1994b): The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. *Arch Gen Psychiatry* 51:486-493.

- Bradwejn J, Koszycki D, Meterissian G (1990): Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. *Can J Psychiatry* 35:83-85.
- Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H (1992b): Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. *Am J Psychiatry* 149:962-964.
- Bradwejn J, Koszycki D, Shriqui C (1991b): Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. *Arch Gen Psychiatry* 48:603-610.
- Brawman MO, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N et al (1997): Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. *Am J Psychiatry* 154:700-702.
- Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA et al (1997): Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. *Arch Gen Psychiatry* 54:246-254.
- Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW et al (2000): SPECT [<sup>123</sup>I]-lomazenil measurement of the benzodiazepine receptor in panic disorder. *Biol Psychiatry* 47:96-106.
- Bremner JD, Staib LH, Kaloupek D, Southwick SM, Soufer R, Charney DS (1999): Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: A positron emission tomography study. *Biol Psychiatry* 45:806-816.
- Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME et al (1998): FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. *Psychiatry Res* 84:1-6.
- Bystritsky A, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY (2001): Functional MRI changes during panic anticipation and imagery exposure. *Neuroreport* 12:3953-3957.
- Cahill L, Haier RJ, White NS, Fallon J, Kilpatrick L, Lawrence C et al (2001): Sex-related difference in amygdala activity during emotionally influenced memory storage. *Neurobiology of Learning and Memory* 75:1-9.
- Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR (1992): Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. *Acta Psychiatr Scand* 86:273-282.
- Chen IW, Dorley JM, Ramjit HG, Pitzenberger SM, Lin JH (1992): Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals. *Drug Metab Dispos* 20:390-395.
- Cheng DT, Knight DC, Smith CN, Stein EA, Helmstetter FJ (2003): Functional MRI of human amygdala activity during Pavlovian fear conditioning: stimulus processing versus response expression. *Behav Neurosci* 117:3-10.
- Chua P, Krams M, Toni I, Passingham R, Dolan R (1999): A functional anatomy of anticipatory anxiety. *Neuroimage* 9:563-571.
- Clark DM (1993): Cognitive mediation of panic attacks induced by biological challenge tests. *Adv Behav Res Ther* 15:75-84.
- Coplan,JD, Klein,DF (1996): Pharmacological probes in panic disorder. In Westenberg,HGM, den Boer,J, Murphy,DL, editors. *Advances in the neurobiology of anxiety disorders*. Chichester: John Wiley & Sons Ltd, pp 173-196.
- Coupland N, Malizia A, Bailey J, Nutt D (1996): Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? [letter; comment]. *Biol Psychiatry* 39:465-466.
- Cowley DS, Hyde TS, Dager SR, Dunner DL (1987): Lactate infusions: the role of baseline anxiety. *Psychiatry Res* 21:169-179.

- Da Costa JM (1871): On irritable heart: a clinical study of a form of functional cardiac disorder and its consequences. *Am J Med Sci* 71:17-52.
- Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LLB, Parvizi J et al (2000): Subcortical and cortical brain activity during the feeling of self-generated emotions. *Nature Neurosci* 3:1049-1056.
- Davidson RJ (2002): Anxiety and affective style: role of prefrontal cortex and amygdala. *Biol Psychiatry* 51:68-80.
- Davidson RJ, Marshall JR, Tomarken AJ, Henriques JB (2000): While a phobic waits: Regional brain electrical and autonomic activity in social phobics during anticipation of public speaking. *Biol Psychiatry* 47:85-95.
- Davis M (1997): Neurobiology of fear responses: The role of the amygdala. *J Neuropsychiatry Clin Neurosci* 9:382-402.
- Davis M (1998): Are different parts of the extended amygdala involved in fear versus anxiety? *Biol Psychiatry* 44:1239-1247.
- De Bellis MD, Casey BJ, Dahl RE, Birmaher B, Williamson DE, Thomas KM et al (2000): A pilot study of amygdala volumes in pediatric generalized anxiety disorder. *Biol Psychiatry* 48:51-57.
- De Cristofaro MT, Sessarego A, Pupi A, Biondi F, Faravelli C (1993): Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. *Biol Psychiatry* 33:505-512.
- de Leeuw AS, Den Boer JA, Slaap BR, Westenberg HG (1996): Pentagastrin has panic-inducing properties in obsessive compulsive disorder. *Psychopharmacology* 126:339-344.
- de Montigny C (1989): Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings [see comments]. *Arch Gen Psychiatry* 46:511-517.
- Deakin JF (1991): Depression and 5HT. *Int Clin Psychopharmacol* 6 Suppl 3:23-28.
- Deakin, JF (1999): Making sense of serotonin (5HT) and its role in common psychopathology. In Tansella, M, Thornicroft, G, editors. *Common Mental Disorders in Primary Care*. London: Routledge, pp 17-33.
- Den Boer JA, Bosker FJ, Slaap BR (2000): Serotonergic drugs in the treatment of depressive and anxiety disorders. *Hum Psychopharmacol Clin Exp* 15:315-336.
- Den Boer, JA, Slaap, BR, Ter Horst, GJ, Cremers, TIFH, Bosker, FJ (2002): Therapeutic armamentarium in anxiety disorders. In D'haenen, H, Den Boer, JA, Willner, P, editors. *Biological Psychiatry*. Chichester: John Wiley & Sons, Ltd, pp 1039-1060.
- Den Boer, JA, van Hout W.J.P.J., Nielen, MMA, Ter Horst, GJ (in press 2003): Neuropsychiatrie van paniekstoornis: een integratie van neurobiologische en psychologische modellen. In Eling, P, De Haan, E, Hijman, R, Schmand, B, editors. *Cognitieve neuropsychiatrie*. Amsterdam: Boom.
- Den Boer JA, Westenberg HG, Kamerbeek WD, Verhoeven WM, Kahn RS (1987): Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. *Int Clin Psychopharmacol* 2:21-32.
- den Boer JA, Westenberg HGM, Klompmakers AA, van Lint LE (1989): Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. *Biol Psychiatry* 26:612-622.
- Dodd J, Kelly JS (1981): The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. *Brain Res* 205:337-350.
- Drevets WC, Videen TQ, MacLeod AK, Haller JW, Raichle ME (1992): PET images of blood flow changes during anxiety: correction [letter]. *Science* 256:1696.
- Ebihara M, Ohba H, Hattori E, Yamada K, Yoshikawa T (2003): Transcriptional activities of cholecystokinin promoter haplotypes and their relevance to panic disorder susceptibility. *Am J Med Genet* 118B:32-35.

- Fernandez M, Pissioti A, Frans O, von Knorring L, Fischer H, Fredrikson M (2001): Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study. *Neurosci Lett* 297:101-104.
- Fischer H, Andersson JLR, Furmark T, Fredrikson M (1998): Brain correlates of an unexpected panic attack: a human positron emission tomographic study. *Neurosci Lett* 251:137-140.
- Fischer H, Wik G, Fredrikson M (1996): Functional neuroanatomy of robbery re-experience: affective memories studied with PET. *Neuroreport* 7:2081-2086.
- Flint A, Bradwejn J, Vaccarino F, Gutkowska J, Palmour R, Koszycki D (2002): Aging and panicogenic response to cholecystinin tetrapeptide: an examination of the cholecystinin system. *Neuropsychopharmacol* 27:663-671.
- Fontaine R, Breton G, Dery R, Fontaine S, Elie R (1990): Temporal lobe abnormalities in panic disorder: an MRI study. *Biol Psychiatry* 27:304-310.
- Fredrikson M, Wik G, Annas P, Ericson K, Stone ES (1995): Functional neuroanatomy of visually elicited simple phobic fear: additional data and theoretical analysis. *Psychophysiology* 32:43-48.
- Fredrikson M, Wik G, Greitz T, Eriksson L, Stone ES, Ericson K et al (1993): Regional cerebral blood flow during experimental phobic fear. *Psychophysiology* 30:126-130.
- Freud S (1895a): Obsessions et Phobies. *Gesammelte Werke, Band I* :343-355.
- Freud S (1895b): Ueber die Berechtigung, von der Neurasthenie einen bestimmten Symptomen-komplex als "Angstneurose" abzutrennen. *Gesammelte Werke, Band I* :315-342.
- Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD (1996): Detecting activations in PET and fMRI: levels of inference and power. *Neuroimage* 4:223-235.
- Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ (1995): Statistical parametric maps in functional imaging: a general linear approach. *Hum Brain Mapp* 2:189-210.
- Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissioti A, Langstrom B et al (2002): Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. *Arch Gen Psychiatry* 59:425-433.
- Genovese CR, Lazar NA, Nichols T (2002): Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *Neuroimage* 15:870-878.
- George MS, Ketter TA, Parekh PI, Herscovitch P, Post RM (1996): Gender differences in regional cerebral blood flow during transient self-induced sadness or happiness. *Biol Psychiatry* 40:859-871.
- Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD (2002): Pentagastrin-induced sleep panic attacks: Panic in the absence of elevated baseline arousal. *Biol Psychiatry* 52:1183-1189.
- Glas,G (2003): A conceptual history of anxiety and depression. In Kasper,S, den Boer,JA, Sitsen,JMA, editors. *Handbook of depression and anxiety*. New York: Marcel Dekker Inc, pp 1-47.
- Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OAC et al (2001): Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. *Arch Gen Psychiatry* 58:556-561.
- Goldberg D (1996): A dimensional model for common mental disorders. *Br J Psychiatry Suppl* :44-49.
- Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM et al (1984): Response to hyperventilation in a group of patients with panic disorder. *Am J Psychiatry* 141:857-861.
- Gorman, JM, Fyer, MR, Liebowitz, MR, Klein, DF (1987): Pharmacological provocation of panic attacks. In Meltzer, HY, editor. *Psychopharmacology: A Third Generation of Progress*. New York: Raven Press, pp 980-983.

- Gorman JM, Kent J, Martinez J, Browne S, Coplan J, Papp LA (2001): Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder - Evidence for a central fear mechanism. *Arch Gen Psychiatry* 58:125-131.
- Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000): Neuroanatomical hypothesis of panic disorder, revised. *Am J Psychiatry* 157:493-505.
- Gorman JM, Liebowitz MR, Fyer AJ, Stein J (1989): A neuroanatomical hypothesis for panic disorder. *Am J Psychiatry* 146:148-161.
- Griez E, de Loof C, Pols H, Zandbergen J, Lousberg H (1990): Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. *Psychiatry Res* 31:193-199.
- Gutmacher LB, Murphy DL, Insel TR (1983): Pharmacologic models of anxiety. *Compr Psychiatry* 24:312-326.
- Haefely W (1994): Benzodiazepines, benzodiazepine receptors and endogenous ligands. In Den Boer JA, Sitsen JMA, editors. *Handbook of depression and anxiety. A biological approach*. New York: Marcel Dekker, pp 573-609.
- Hamilton M (1959): The assessment of anxiety states by rating. *Br J Med Psychol* 32:50-55.
- Hamilton M (1967): Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 6:278-296.
- Hamilton SP, Slager SL, Helleby L, Heiman GA, Klein DF, Hodge SE et al (2001): No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. *Mol Psychiatry* 6:59-65.
- Haradahira T, Inoue O, Kobayashi K, Suzuki K (1998): Synthesis and evaluation of <sup>11</sup>C-labeled nonpeptide antagonists for cholecystokinin receptors: [<sup>11</sup>C]L-365,260 and [<sup>11</sup>C]L-365,346. *Nucl Med Biol* 25:203-208.
- Hariri AR, Mattay VS, Tessitore A, Fera F, Weinberger DR (2003): Neocortical modulation of the amygdala response to fearful stimuli. *Biol Psychiatry* 53:494-501.
- Harro J, Pold M, Vasar E (1990): Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. *Naunyn Schmiedebergs Arch Pharmacol* 341:62-67.
- Harro J, Vasar E, Bradwejn J (1993): CCK in animal and human research on anxiety. *Trends Pharmacol Sci* 14:244-249.
- Hattori E, Ebihara M, Yamada K, Ohba H, Shibuya H, Yoshikawa T (2001a): Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. *Mol Psychiatry* 6:465-470.
- Hattori E, Yamada K, Toyota T, Yoshitsugu K, Toru M, Shibuya H et al (2001b): Association studies of the CT repeat polymorphism in the 5' upstream region of the cholecystokinin B receptor gene with panic disorder and schizophrenia in Japanese subjects. *Am J Med Genet* 105:779-782.
- Hirschfeld RMA (2000): Sertraline in the treatment of anxiety disorders. *Depression and Anxiety* 11:139-157.
- Ise K, Akiyoshi J, Horinouchi Y, Tsutsumi T, Isogawa K, Nagayama H (2003): Association between the CCK-A receptor gene and panic disorder. *Am J Med Genet* 118B:29-31.
- Ivy AC, Oldberg E (1928): Hormone mechanism for gallbladder contraction and evacuation. *Am J Physiol* 86:599-613.
- Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J (1999): Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: A comparison of two time points. *Biol Psychiatry* 45:872-882.

- Johanson A, Gustafson L, Passant U, Risberg J, Smith G, Warkentin S et al (1998): Brain function in spider phobia. *Psychiatry Res Neuroimaging* 84:101-111.
- Kalin NH, Shelton SE, Davidson RJ, Kelley AE (2001): The primate amygdala mediates acute fear but not the behavioral and physiological components of anxious temperament. *J Neurosci* 21:2067-2074.
- Karknias CD, Block GA, Reines S, Bradwejn J (1989): Neurobiology of panic disorder [letter]. *Am J Psychiatry* 146:1357.
- Kaschka W, Feistel H, Ebert D (1995): Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. *J Psychiatr Res* 29:427-434.
- Kastrop A, Li TQ, Glover GH, Kruger G, Moseley ME (1999): Gender differences in cerebral blood flow and oxygenation response during focal physiologic neural activity. *J Cereb Blood Flow Metab* 19:1066-1071.
- Katschnig H (1999): Anxiety neurosis, panic disorder or what? In Nutt, DJ, Ballenger, JC, Lepine, J-P, editors. *Panic Disorder: Clinical Diagnosis, Management and Mechanisms*. London: Martin Dunitz Ltd, pp 1-8.
- Katzman MA, Duffin J, Shlik J, Bradwejn J (2002): The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers. *Neuropsychopharmacol* 26:824-831.
- Kellner M, Yassouridis A, Hua Y, Wendrich M, Naber D, Wiedemann K (2002): Trait dissociation affects the behavioral response to cholecystokinin tetrapeptide in healthy man. *Psychiatry Res* 111:93-96.
- Kendell RE (1975): The concept of disease and its implications for psychiatry. *Br J Psychiatry* 127:305-315.
- Kent JM, Papp LA, Martinez JM, Browne ST, Coplan JD, Klein DF et al (2001): Specificity of panic response to CO<sub>2</sub> inhalation in panic disorder: A comparison with major depression and premenstrual dysphoric disorder. *Am J Psychiatry* 158:58-67.
- Klein, DF (1981): Anxiety reconceptualized. In Klein, DF, Rabkin, J, editors. *Anxiety: New Research and Changing Concepts*. New York: Raven Press, pp 235-263.
- Klein DF, Klein HM (1989): The utility of the panic disorder concept. *Eur Arch Psychiatry Neurol Sci* 238:268-279.
- Knott VJ, Mahoney C, Gunnarsson T, Bradwejn J, Shlik J (2002): Acute cholecystokinin effects on event-related potentials in healthy volunteers. *Hum Psychopharmacol* 17:285-291.
- Koszycki D, Bradwejn J, Bourin M (1991): Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. *Eur Neuropsychopharmacol* 1:137-141.
- Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A et al (1995): A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. *Biol Psychiatry* 37:462-466.
- Kronenberg G, Schredl M, Fiedler K, Heuser I (2001): In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep. *Depress Anxiety* 14:141-144.
- Kuikka JT, Pitkanen A, Lepola U, Partanen K, Vainio P, Bergstrom KA et al (1995): Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. *Nucl Med Commun* 16:273-280.
- Layton ME, Friedman SD, Dager SR (2001): Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment. *Depress Anxiety* 14:251-254.
- Le Melleo J, Jhangri GS, Lott P, Tait GR, McManus K, Geddes M et al (2001a): Effect of medroxyprogesterone pretreatment on pentagastrin-induced panic symptoms in females with panic disorder. *Psychiatry Res* 101:237-242.
- Le Melleo JM, Arthur H, Dalton J, Woo C, Lipton N, Bellavance F et al (2001b): The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. *J Psychosom Res*

- 51:513-520.
- LeDoux J (1996): Emotional networks and motor control: a fearful view. *Prog Brain Res* 107:437-446.
  - LeDoux J (1998): Fear and the brain: where have we been, and where are we going? [see comments]. *Biol Psychiatry* 44:1229-1238.
  - LeDoux JE (1994): Emotion, memory and the brain. *Sci Am* 270:32-39.
  - LeDoux,JE (2002): *Synaptic self: how our brains become who we are* . New York: Viking.
  - LeDoux JE, Cicchetti P, Xagoraris A, Romanski LM (1990): The lateral amygdaloid nucleus: sensory interface of the amygdala in fear conditioning. *J Neurosci* 10:1062-1069.
  - LeDoux JE, Iwata J, Cicchetti P, Reis DJ (1988): Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. *J Neurosci* 8:2517-2529.
  - Lee MA, Flegel P, Greden JF, Cameron OG (1988): Anxiogenic effects of caffeine on panic and depressed patients. *Am J Psychiatry* 145:632-635.
  - Lepola U, Nousiainen U, Puranen M, Riekkinen P, Rimon R (1990): EEG and CT findings in patients with panic disorder. *Biol Psychiatry* 28:721-727.
  - Levin P, Lazrove S, Van der Linden KB (1999): What psychological testing and neuroimaging tell us about the treatment of Posttraumatic Stress Disorder by Eye Movement Desensitization and Reprocessing. *J Anxiety Disord* 13:159-172.
  - Liberzon I, Taylor SF, Amdur R, Jung TD, Chamberlain KR, Minoshima S et al (1999): Brain activation in PTSD in response to trauma-related stimuli. *Biol Psychiatry* 45:817-826.
  - Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G et al (1985): Lactate provocation of panic attacks. II. Biochemical and physiological findings. *Arch Gen Psychiatry* 42:709-719.
  - Londeborg PD, Wolkow RM, Smith WT, Duboff E, England D, Ferguson JM et al (1998): Sertraline in the treatment of panic disorder - A multi-site, double-blind, placebo-controlled, fixed-dose investigation. *Br J Psychiatry* 173:54-60.
  - Maclean PD (1949): Psychosomatic disease and the "visceral brain"; recent developments bearing on the Papez theory of emotion. *Psychosom Med* 11:338-353.
  - Maddock RJ (1999): The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. *Trends Neurosci* 22:310-316.
  - Malizia AL (1999): What do brain imaging studies tell us about anxiety disorders? *J Psychopharmacol* 13:372-378.
  - Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ (1998): Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. *Arch Gen Psychiatry* 55:715-720.
  - Margraf J, Ehlers A, Roth WT (1986): Sodium lactate infusions and panic attacks: a review and critique. *Psychosom Med* 48:23-51.
  - Massana G, Serra-Grabulosa JM, Salgado-Pineda P, Gasto C, Junque C, Massana J et al (2003): Parahippocampal gray matter density in panic disorder: a voxel-based morphometric study. *Am J Psychiatry* 160:566-568.
  - Massana G, Gasto C, Junque C, Mercader J, Gomez B, Massana J et al (2002): Reduced levels of creatine in the right medial temporal lobe region of panic disorder patients detected with (1)h magnetic resonance spectroscopy. *Neuroimage* 16:836.
  - Massana J, Lopez-Risueno JA, Masana G, Marcos T, Gonzalez L, Otero A (2001): Subtyping of panic disorder patients with bradycardia. *Eur Psychiatry* 16:109-114.
  - Mataix-Cols D, Cullen S, Lange K, Zelaya F, Andrew C, Amaro E et al (2003): Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers. *Biol Psychiatry* 53:482-493.

- Mathew RJ, Wilson WH (1990a): Anxiety and cerebral blood flow. *Am J Psychiatry* 147:838-849.
- Mathew RJ, Wilson WH (1990b): Behavioral and cerebrovascular effects of caffeine in patients with anxiety disorders. *Acta Psychiatr Scand* 82:17-22.
- McCann UD, Slate SO, Geraci M, RoscowTerrill D, Uhde TW (1997): A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. *Neuropsychopharmacol* 16:229-237.
- McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ (1994): Functional anatomy of obsessive-compulsive phenomena. *Br J Psychiatry* 164:459-468.
- McManus K, Tait GR, Bellavance F, Le Melleo JM (2001): Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin. *J Affect Disord* 66:273-279.
- Meyer JH, Swinson R, Kennedy SH, Houle S, Brown GM (2000): Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. *Psychiatry Res Neuroim* 98:133-143.
- Morel BA (1866): *Du Delire Emotif*. *Archives generales de medecine* 1:385-402.
- Morris JS, Scott SK, Dolan RJ (1999): Saying it with feeling: neural responses to emotional vocalizations. *Neuropsychologia* 37:1155-1163.
  
- Nashold BSJ, Wilson WP, Slaughter DG (1969): Sensations evoked by stimulation in the mid-brain of man. *J Neurosurg* 30:14-24.
- Nitschke JB, Heller W, Palmieri PA, Miller GA (1999): Contrasting patterns of brain activity in anxious apprehension and anxious arousal. *Psychophysiology* 36:628-637.
- Nordahl TE, Semple WE, Gross M, Mellman TA, Stein MB, Goyer P et al (1990): Cerebral glucose metabolic differences in patients with panic disorder. *Neuropsychopharmacol* 3:261-272.
- Nordahl TE, Stein MB, Benkelfat C, Semple WE, Andreason P, Zametkin A et al (1998): Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders. *Biol Psychiatry* 44:998-1006.
- Nutt, DJ, Ballenger, JC, Lepine, J-P (1999): *Panic Disorder: Clinical Diagnosis, Management and Mechanisms*. London: Martin Dunitz Ltd.
- Nutt DJ, Glue P, Lawson C, Wilson S (1990): Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder [see comments]. *Arch Gen Psychiatry* 47:917-925.
  
- O'Rourke D, Fahy TJ, Prescott P (1996): The Galway Study of Panic Disorder. IV. Temporal stability of diagnosis by present state examination test-retest. *Br J Psychiatry* 169:98-100.
- Ochsner KN, Bunge SA, Gross JJ, Gabrieli JD (2002): Rethinking feelings: an fMRI study of the cognitive regulation of emotion. *J Cogn Neurosci* 14:1215-1229.
- Olsson M, Ho HP, Annerbrink K, Thylefors J, Eriksson E (2002): Respiratory responses to intravenous infusion of sodium lactate in male and female Wistar rats. *Neuropsychopharmacol* 27:85-91.
- Ontiveros A, Fontaine R, Breton G, Elie R, Fontaine S, Dery R (1989): Correlation of severity of panic disorder and neuroanatomical changes on magnetic resonance imaging. *J Neuropsychiatry Clin Neurosci* 1:404-408.
- Otte C, Kellner M, Arlt J, Jahn H, Holsboer F, Wiedemann K (2002): Prolactin but not ACTH increases during sodium lactate-induced panic attacks. *Psychiatry Res* 109:201-205.
  
- Papez JW (1937): A proposed mechanism of emotion. *Arch Neurol Psychiatry* 38:725-743.
- Paquette V, Levesque J, Mensour B, Leroux JM, Beaudoin G, Bourgouin P et al (2003): "Change the mind and you change the brain": effects of cognitive-behavioral therapy on the neural correlates of spider phobia. *Neuroimage* 18:401-409.

- Paulson OB (2002): Blood-brain barrier, brain metabolism and cerebral blood flow. *Eur Neuropsychopharmacol* 12:495-501.
- Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S et al (1995): [<sup>18</sup>F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. *Br J Psychiatry* 166:244-250.
- Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L (2002): Antipanic drug modulation of 35% CO<sub>2</sub> hyperreactivity and short-term treatment outcome. *J Clin Psychopharmacol* 22:300-308.
- Pissiota A, Frans O, Fernandez M, von Knorring L, Fischer H, Fredrikson M (2002): Neurofunctional correlates of posttraumatic stress disorder: a PET symptom provocation study. *Eur Arch Psychiatry Clin Neurosci* 252:68-75.
- Pitts FN, McClure JN (1967): Lactate metabolism in anxiety neurosis. *N Engl J Med* 277:1329-1336.
- Pohl RB, Wolkow RM, Clary CM (1998): Sertraline in the treatment of panic disorder: A double-blind multicenter trial. *Am J Psychiatry* 155:1189-1195.
- Pollack MH, Marzol PC (2000): Panic: course, complications and treatment of panic disorder. *J Psychopharmacology* 14:S25-S30.
- Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998): Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. *Arch Gen Psychiatry* 55:1010-1016.
- Pols H, Verburg K, Griez E (1994): Carbon-Dioxide-Induced Panic. *Am J Psychiatry* 151:292-293.
- Ponto LLB, Kathol RG, Kettelkamp R, Watkins GL, Richmond JCW, Clark J et al (2002): Global cerebral blood flow after CO<sub>2</sub> inhalation in normal subjects and patients with panic disorder determined with [<sup>15</sup>O]water and PET. *J Anxiety Disord* 16:247-258.
- Radu D, Ahlin A, Svanborg P, Lindefors N (2002): Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels. *Psychopharmacology* 161:396-403.
- Radu D, Ahlin A, Svanborg P, Lindefors N (2003): Pentagastrin test for anxiety—psychophysiology and personality. *Psychopharmacology* 166:139-145.
- Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2001): Sertraline treatment of panic disorder: results of a long-term study. *Acta Psychiatr Scand* 104:289-298.
- Rassovsky Y, Kushner MG (2003): Carbon dioxide in the study of panic disorder: issues of definition, methodology, and outcome. *J Anxiety Disord* 17:1-32.
- Rauch SL, Savage CR, Alpert NM, Fischman AJ, Jenike MA (1997): The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. *Biol Psychiatry* 42:446-452.
- Rauch SL, Savage CR, Alpert NM, Miguel EC, Baer L, Breiter HC et al (1995): A positron emission tomographic study of simple phobic symptom provocation. *Arch Gen Psychiatry* 52:20-28.
- Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR et al (1996): A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. *Arch Gen Psychiatry* 53:380-387.
- Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA (2002): Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. *Neuropsychopharmacol* 27:782-791.
- Rehfeld JF (2000): Cholecystokinin and panic disorder - three unsettled questions. *Reg Peptides* 93:79-83.
- Reiman EM (1997): The application of positron emission tomography to the study of normal and pathologic emotions. *J Clin Psychiatry* 58 Suppl 16:4-12.

- Reiman EM, Fusselman MJ, Fox PT, Raichle ME (1989a): Neuroanatomical correlates of anticipatory anxiety [published erratum appears in *Science* 1992 Jun 19;256(5064):1696]. *Science* 243:1071-1074.
- Reiman EM, Lane RD, Ahern GL, Schwartz GE, Davidson RJ, Friston KJ et al (1997): Neuroanatomical correlates of externally and internally generated human emotion. *Am J Psychiatry* 154:918-925.
- Reiman EM, Raichle ME, Butler FK, Herscovitch P, Robins E (1984): A focal brain abnormality in panic disorder, a severe form of anxiety. *Nature* 310:683-685.
- Reiman EM, Raichle ME, Robins E, Butler FK, Herscovitch P, Fox P et al (1986): The application of positron emission tomography to the study of panic disorder. *Am J Psychiatry* 143:469-477.
- Reiman EM, Raichle ME, Robins E, Mintun MA, Fusselman MJ, Fox PT et al (1989b): Neuroanatomical correlates of a lactate-induced anxiety attack. *Arch Gen Psychiatry* 46:493-500.
- Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al (2003): Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. *J Neurosci* 23:349-357.
- Sanchez-Fernandez C, Gonzalez C, Mercer LD, Beart PM, Ruiz-Gayo M, Fernandez-Alfonso MS (2003): Cholecystokinin Induces Cerebral Vasodilatation via Presynaptic CCK<sub>2</sub> Receptors: New Implications for the Pathophysiology of Panic. *J Cereb Blood Flow Metab* 23:364-370.
- Saxena S, Brody AL, Schwartz JM, Baxter LR (1998): Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. *Br J Psychiatry Suppl* :26-37.
- Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N et al (2002): Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. *Arch Gen Psychiatry* 59:250-261.
- Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O (1994): Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. *Eur Arch Psychiatry Clin Neurosci* 244:49-51.
- Schwartz JM, Stoessel PW, Baxter LRJ, Martin KM, Phelps ME (1996): Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. *Arch Gen Psychiatry* 53:109-113.
- Sheehan DV (1999): Current concepts in the treatment of panic disorder. *J Clin Psychiatry* 60 Suppl. 18:16-21.
- Shin LM, McNally RJ, Kosslyn SM, Thompson WL, Rauch SL, Alpert NM et al (1999): Regional cerebral blood flow during script-driven imagery in childhood sexual abuse-related PTSD: A PET investigation. *Am J Psychiatry* 156:575-584.
- Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997): Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. *J Psychiatry Neurosci* 22:332-340.
- Shlik J, Zhou YP, Koszycki D, Vaccarino FJ, Bradwejn J (1999): Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. *J Psychopharmacol* 13:385-390.
- Sinton CM (1988): Cholecystokinin and cholecystokinin antagonists enhance postsynaptic excitability in the dentate gyrus. *Peptides* 9:1049-1053.
- Spitzer RL, Endicott J, Robins E (1978): Research diagnostic criteria: rationale and reliability. *Arch Gen Psychiatry* 35:773-782.
- Stewart RS, Devous-MD S, Rush AJ, Lane L, Bonte FJ (1988): Cerebral blood flow changes during sodium-lactate-induced panic attacks. *Am J Psychiatry* 145:442-449.
- Strohle A, Kellner M, Holsboer F, Wiedemann K (1999): Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensi-

- tivity in panic disorder. *Biol Psychiatry* 45:321-326.
- Strohle A, Kellner M, Holsboer F, Wiedemann K (2001): Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. *Am J Psychiatry* 158:1514-1516.
  - Strohle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G et al (2003): Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. *Arch Gen Psychiatry* 60:161-168.
  - Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL et al (1992): Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. *Arch Gen Psychiatry* 49:690-694.
  - Talairach, J, Tournoux, P (1988): *Co-Planar Stereotaxic Atlas of the Human Brain*. New York: Thieme.
  - Tarlo SM, Poonai N, Binkley K, Antony MM, Swinson RP (2002): Responses to panic induction procedures in subjects with multiple chemical sensitivity/idiopathic environmental intolerance: understanding the relationship with panic disorder. *Environ Health Perspect* 110 Suppl 4:669-671.
  - Tillfors M, Furmark T, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B et al (2001): Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. *Am J Psychiatry* 158:1220-1226.
  - Uhde TW, Kellner CH (1987): Cerebral ventricular size in panic disorder. *J Affect Disord* 12:175-178.
  - Valenca AM, Nardi AE, Nascimento I, Zin WA, Lopes FL, Mezzasalma MA et al (2002a): Early carbon dioxide challenge test may predict clinical response in panic disorder. *Psychiatry Res* 112:269-272.
  - Valenca AM, Nardi AE, Nascimento I, Zin WA, Versiani M (2002b): Respiratory panic disorder subtype and sensitivity to the carbon dioxide challenge test. *Braz J Med Biol Res* 35:783-788.
  - Valenca AM, Nardi AE, Nascimento I, Zin WA, Versiani M (2002c): Carbon dioxide test as an additional clinical measure of treatment response in panic disorder. *Arq Neuropsiquiatr* 60:358-361.
  - van Balkom AJLM, Bakker A, Spinhoven P, Blaauw BMJW, Smeenk S, Ruesink B (1997): A meta-analysis of the treatment of panic disorder with or without agoraphobia: A comparison of psychopharmacological, cognitive-behavioral, and combination treatments. *J Nerv Ment Dis* 185:510-516.
  - van den Hout MA, Griez E (1984): Panic symptoms after inhalation of carbon dioxide. *Br J Psychiatry* 144:503-507.
  - Van der Linden LG, Van Heerden B, Warwick J, Wessels C, Van Kradenburg J, Zungu DN et al (2000): Functional brain imaging and pharmacotherapy in social phobia: Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. *Progress in Neuro Psychopharmacol Biol Psychiatry* 24:419-438.
  - van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS (1996a): Cholecystokinin in anxiety. *Eur Neuropsychopharmacol* 6:263-280.
  - van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS (1996b): The panic-inducing properties of the cholecystokinin tetrapeptide CCK<sub>4</sub> in patients with panic disorder. *Eur Neuropsychopharmacol* 6:187-194.
  - van Megen HJ, Westenberg HG, Den Boer JA, Slaap B, Scheepmakers A (1997a): Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. *Psychopharmacology* 129:357-364.

- van Megen HJ, Westenberg HG, Den Boer JA, Slaap B, van Es RF, Pande AC (1997b): The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. *Psychopharmacology* 129:243-248.
- Van Megen HJGM, Westenberg HGM, den Boer JA, Haigh JRM, Traub M (1994): Pentagastrin Induced Panic Attacks - Enhanced Sensitivity in Panic Disorder Patients. *Psychopharmacology* 114:449-455.
- van Praag HM (1989): Moving ahead yet falling behind. A critical appraisal of some trends in contemporary depression research. *Neuropsychobiol* 22:181-193.
- van Praag HM (2000): Nosologomania: a disorder of psychiatry. *World J Biol Psychiatry* 1:151-158.
- van Praag HM, Asnis GM, Kahn RS, Brown SL, Korn M, Friedman JM et al (1990): Nosological tunnel vision in biological psychiatry. A plea for a functional psychopathology. *Ann N Y Acad Sci* 600:501-510.
- van Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A et al (1987): Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. *J Affect Disord* 13:1-8.
- van Vliet IM, Den Boer JA, Westenberg HG, Slaap BR (1996): A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. *J Clin Psychopharmacol* 16:299-306.
- Vythilingam M, Anderson ER, Goddard A, Woods SW, Staib LH, Charney DS et al (2000): Temporal lobe volume in panic disorder - a quantitative magnetic resonance imaging study. *Psychiatry Res Neuroim* 99:75-82.
- Westenberg, HG, Den Boer, JA, Murphy, DL (1996): *Advances in the neurobiology of anxiety disorders*. Chichester: John Wiley & Sons Ltd.
- Westphal C (1872): Die Agoraphobie. *Archiv fur Psychiatrie und Nervenkrankheiten* :138-161.
- Wiedemann K, Jahn H, Yassouridis A, Kellner M (2001): Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. *Arch Gen Psychiatry* 58:371-377.
- Wik G, Fredrikson M, Ericson K, Eriksson L, Stone ES, Greitz T (1993): A functional cerebral response to frightening visual stimulation. *Psychiatry Res* 50:15-24.
- Windmann S (1998): Panic disorder from a monistic perspective: integrating neurobiological and psychological approaches. *J Anxiety Disord* 12:485-507.
- Woods SW, Koster K, Krystal JK, Smith EO, Zubal IG, Hoffer PB et al (1988): Yohimbine alters regional cerebral blood flow in panic disorder [letter]. *Lancet* 2:678.
- Worsley KJ, Marret S, Neelin P, Vandal AC, Friston KJ, Evans AC (1996): A unified statistical approach for determining significant signals in images of cerebral activation. *Hum Brain Mapp* 4:58-73.
- Yamada K, Hattori E, Shimizu M, Sugaya A, Shibuya H, Yoshikawa T (2001): Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes in panic disorder. *J Neural Transm* 108:837-848.
- Yeragani VK, Rainey-JM J, Pohl R, Balon R, Berchou R, Jolly S et al (1988): Preinfusion anxiety and laboratory-induced panic attacks in panic disorder patients. *J Clin Psychiatry* 49:302-306.
- Yeragani VK, Rao R, Jayaraman A, Pohl R, Balon R, Glitz D (2002): Heart rate time series: decreased chaos after intravenous lactate and increased non-linearity after isoproterenol in normal subjects. *Psychiatry Res* 109:81-92.
- Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N et al (2001): Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. *Neuropsychopharmacol* 25:699-703.